Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $867.21 million. The enterprise value is $212.44 million.
Important Dates
The next estimated earnings date is Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 88.76 million shares outstanding. The number of shares has increased by 1.76% in one year.
| Current Share Class | 88.76M |
| Shares Outstanding | 88.76M |
| Shares Change (YoY) | +1.76% |
| Shares Change (QoQ) | +0.46% |
| Owned by Insiders (%) | 1.61% |
| Owned by Institutions (%) | 73.61% |
| Float | 65.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.73 |
| Forward PS | 7.83 |
| PB Ratio | 4.88 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.06, with a Debt / Equity ratio of 0.12.
| Current Ratio | 6.06 |
| Quick Ratio | 5.81 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -200.81 |
Financial Efficiency
Return on equity (ROE) is -94.82% and return on invested capital (ROIC) is -60.74%.
| Return on Equity (ROE) | -94.82% |
| Return on Assets (ROA) | -25.33% |
| Return on Invested Capital (ROIC) | -60.74% |
| Return on Capital Employed (ROCE) | -48.86% |
| Weighted Average Cost of Capital (WACC) | 5.60% |
| Revenue Per Employee | $259,546 |
| Profits Per Employee | -$1.07M |
| Employee Count | 260 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $297,000 in taxes.
| Income Tax | 297,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.35% in the last 52 weeks. The beta is 0.24, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +68.35% |
| 50-Day Moving Average | 8.51 |
| 200-Day Moving Average | 8.76 |
| Relative Strength Index (RSI) | 66.30 |
| Average Volume (20 Days) | 1,539,408 |
Short Selling Information
The latest short interest is 14.20 million, so 16.00% of the outstanding shares have been sold short.
| Short Interest | 14.20M |
| Short Previous Month | 14.38M |
| Short % of Shares Out | 16.00% |
| Short % of Float | 21.78% |
| Short Ratio (days to cover) | 9.31 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $67.48 million and -$278.67 million in losses. Loss per share was -$3.18.
| Revenue | 67.48M |
| Gross Profit | -183.65M |
| Operating Income | -303.63M |
| Pretax Income | -278.37M |
| Net Income | -278.67M |
| EBITDA | -302.60M |
| EBIT | -303.63M |
| Loss Per Share | -$3.18 |
Full Income StatementBalance Sheet
The company has $667.24 million in cash and $20.46 million in debt, with a net cash position of $646.78 million or $7.29 per share.
| Cash & Cash Equivalents | 667.24M |
| Total Debt | 20.46M |
| Net Cash | 646.78M |
| Net Cash Per Share | $7.29 |
| Equity (Book Value) | 174.14M |
| Book Value Per Share | 1.98 |
| Working Capital | 591.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$64.06 million and capital expenditures -$6.64 million, giving a free cash flow of -$70.70 million.
| Operating Cash Flow | -64.06M |
| Capital Expenditures | -6.64M |
| Depreciation & Amortization | 1.03M |
| Net Borrowing | n/a |
| Free Cash Flow | -70.70M |
| FCF Per Share | -$0.80 |
Full Cash Flow StatementMargins
| Gross Margin | -272.15% |
| Operating Margin | -449.94% |
| Pretax Margin | -412.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.76% |
| Shareholder Yield | -1.76% |
| Earnings Yield | -32.43% |
| FCF Yield | -8.23% |
Analyst Forecast
The average price target for Kura Oncology is $25.56, which is 161.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.56 |
| Price Target Difference | 161.62% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 80.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of -1.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.82 |
| Piotroski F-Score | 2 |
